36 post-surgery using the Mann-Whitney test. Pearson correlation coefficients were calculated between utility scores and the KOOS overall, KOOS quality of life and VAS scores at each time-point. RESULTS: Significantly higher utility scores were observed in KOOS responders compared to non-responders at Months 30 (0.817 vs. 0.691, n = 25/14, p = 0.004) and 36 (0.775 vs. 0.618, n = 19/6, p = 0.006) and in VAS responders compared to non-responders at Months 24 (0.827 vs. 0.701, n = 17/9, p = 0.038) and 36 (0.764 vs. 0.600, n = 21/4, p = 0.015). A similar trend of borderline significance was measured at Months 24 (using KOOS, 0.818 vs. 0.728, n = 16/10, p = 0.136) and 30 (using VAS, 0.800 vs. 704, n = 21/4, p = 0.053). Utility scores correlated best with the KOOS overall (Pearson coefficients ranged from 0.579 to 0.721, p-values < 0.01) and VAS scores (-0.514 to -0.671, p-values < 0.01). CONCLUSIONS: Gaps in utility scores between responders (= successful surgery) and nonresponders ranged from 0.091 to 0.164. This finding validates the assumption made in a previous Health Technology Assessment on Autologous Chondrocytes Implantation. Consistent gaps and significant correlations with validated tools provide valuable information for future economic modeling of CCI. OBJECTIVES: QOL (quality of life) is critical in the management of patients with rheumatoid arthritis (RA). To evaluate the QOL of RA patients with different background, we evaluated the QOL by using Japanese version of EuroQol (EQ-5D) in a large observational cohort study of Japanese RA patients, IORRA.
tion coefficients were calculated between utility scores and the KOOS overall, KOOS quality of life and VAS scores at each time-point. RESULTS: Significantly higher utility scores were observed in KOOS responders compared to non-responders at Months 30 (0.817 vs. 0.691, n = 25/14, p = 0.004) and 36 (0.775 vs. 0.618, n = 19/6, p = 0.006) and in VAS responders compared to non-responders at Months 24 (0.827 vs. 0.701, n = 17/9, p = 0.038) and 36 (0.764 vs. 0.600, n = 21/4, p = 0.015). A similar trend of borderline significance was measured at Months 24 (using KOOS, 0.818 vs. 0.728, n = 16/10, p = 0.136) and 30 (using VAS, 0.800 vs. 704, n = 21/4, p = 0.053). Utility scores correlated best with the KOOS overall (Pearson coefficients ranged from 0.579 to 0.721, p-values < 0.01) and VAS scores (-0.514 to -0.671, p-values < 0.01). CONCLUSIONS: Gaps in utility scores between responders (= successful surgery) and nonresponders ranged from 0.091 to 0.164. This finding validates the assumption made in a previous Health Technology Assessment on Autologous Chondrocytes Implantation. Consistent gaps and significant correlations with validated tools provide valuable information for future economic modeling of CCI.
PMS55 EURO QOL (EQ-5D) BASED QOL (QUALITY OF LIFE) IN 5,023 JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS (RA) PATIENTS IN AN OBSERVATIONAL COHORT IORRA
Hoshi D 1 , Igarashi A 2 , Orihara S 2 , Tsutani K 2 , Inoue E 1 , Momohara S 1 , Hara M 1 , Kamatani N 1 ,Yamanaka H 1 1 Tokyo women's medical university, Shinjyuku, Tokyo, Japan, 2 The University of Tokyo, Bunkyo, Tokyo, Japan OBJECTIVES: QOL (quality of life) is critical in the management of patients with rheumatoid arthritis (RA). To evaluate the QOL of RA patients with different background, we evaluated the QOL by using Japanese version of EuroQol (EQ-5D) in a large observational cohort study of Japanese RA patients, IORRA.
METHODS:
We have established a large observational cohort of RA patients IORRA (Institute Of Rheumatology Rheumatoid Arthritis) in the Institute of Rheumatology Tokyo Women's Medical University since 2000. Essentially all RA patients who consulted there were registered, and clinical parameters including the disease activity, use of drugs and the occurrence of adverse events in daily clinical settings were assessed biannually based on patient's report, physician's examination and laboratory data. In this cohort, we evaluated the QOL of RA patients by EQ-5D, disease activity by DAS28, and disability by JHAQ, and then we analyzed the related factors for EQ-5D by Spearman's correlation. RESULTS: In September 2007, a total 5023 RA patients (female 84.2%, average 58.02 years-old, average disease duration 11.26 years, rheumatoid factor positive 74.8%, patients taking steroid, methotrexate and biologics were 51.0%, 63.6%, and 4.3%, respectively) fulfilled the questionnaire of EQ-5D. Mean Ϯ SD of EQ-5D, DAS28 and JHAQ was 0.757 Ϯ 0.178, 3.28 Ϯ 1.147 and 0.737 Ϯ 0.769, respectively, EQ-5D was worse in female (0.75 Ϯ 0.177) than in male (0.798 Ϯ 0.177) patients, and worse in rheumatoid factor positive (0.75 Ϯ 0.178) than negative (0.782 Ϯ 0.175) patients. EQ-5D became worse by older age and longer disease duration. No clear relationship was identified between EQ-5D and medications including corticosteroid, methotrexate or biologics in this cross-sectional analysis. CONCLUSIONS: EQ-5D based QOL was analyzed in a large number of Japanese RA patients using IORRA cohort.
PMS56 FIBROMYALGIA MOLDOFSKY QUESTIONNAIRE (FMQ): VALIDATION OF A TOOL TO AID DIAGNOSIS
Le Lay K 1 , Moldofsky H 2 , Boussetta S 1 , Taieb C 1 1 Pierre Fabre, Billancourt, France, 2 Centre for Sleep and Chronobiology, Toronto, ON, Canada OBJECTIVES: The absence of objective signs and lack of tests make patient complaints fundamental to a presumptive diagnosis of fibromyalgia. To make diagnosis easier, H. Moldofsky has developed a questionnaire of 6 items related to diffuse pain, fatigue, psychological distress, unrestorative sleep and impaired well-being. To validate the FMQ (Fibromyalgia Moldofsky Questionnaire) as a tool to aid diagnosis, METHODS: A representative sample of 1500 subjects from the general UK population was constituted using the quota method. The FMQ questionnaire, was administered along with two validated questionnaires (LFESSQ London Fibromyalgia Epidemiology Study Screening Questionnaire and CES-D Center for Epidemiologic Studies Depression Scale) and a questionnaire assessing a decline in the restorative effects of sleep (SQA Sleep Quality Assessment). The maximum score of 18 reflected a strong presumption of fibromyalgia syndrome. Internal consistency, structural and clinical validity were tested. The sensitivity and specificity were also assessed, RESULTS: Internal consistency was satisfactory (aCronbach > 0.7). The items composing each dimension were pertinent to the dimension that they represented (R > 0.4) and were not correlated with any other dimension. Subjects responding positively on the LFESSQ had an FMQ score that was significantly higher than subjects who responded negatively (8.6 [7.9-9.3] vs 4.1 [3.9-4.3], p < 0.001). Similar differences were observed between those subjects who had or did not have probable depressive symptoms (8.0 [7.4-8.6 ] vs 4.0 [3.8-4.2], p < 0.001) and between subjects experiencing a decline in the restorative effect of sleep or not (7.3 [7.0-7.6 ] vs 3.5 [3.3-3.7], p < 0.001).The FMQ had a sensitivity of 46 to 54%, depending on the specific dimension and questionnaire studied. Specificity was optimal (90 to 95%), CONCLU-SIONS: The results observed during this psychometric validation showed that the FMQ questionnaire responded to the objectives that we had established and therefore allows referring physicians to send subjects with presumed fibromyalgia to specialist investigation centres.
PMS57 VALIDITY AND RESPONSIVENESS OF THE WORK PRODUCTIVITY SURVEY: A NOVEL DISEASE-SPECIFIC INSTRUMENT ASSESSING WORK PRODUCTIVITY WITHIN AND OUTSIDE THE HOME IN SUBJECTS WITH RHEUMATOID ARTHRITIS
Osterhaus J 1 , Purcaru O 2 , Richard L 3 1 Wasatch Health Outcomes, Park City, UT, USA, 2 UCB, Braine l'Alleud, Belgium, 3 UCB Celltech, Slough, UK OBJECTIVES: To determine the validity and responsiveness of the novel disease-specific Work Productivity Survey (WPS-RA) in patients with active rheumatoid arthritis (RA). The WPS-RA captures the RA impact on work and home-related.productivity. METHODS: A total of 220 RA subjects were randomized to 400 mg of subcutaneous certolizumab pegol or placebo every 4 weeks, for 24 weeks (wks). The WPS-RA was completed monthly starting Baseline (BL) until withdrawal/completion. Validity was evaluated at BL, using the known-groups approach. Mean WPS-RA responses at BL were compared between subjects with different levels of physical function or health-related quality-oflife (HRQoL). Groups were defined by the median-cut of subjects' scores to Health Assessment Questionnaire Disability Index (HAQ-DI) and SF-36 (the physical and mental component sum-
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